Chapter 55 Painful Peripheral Neuropathies Flashcards Preview

Essentials of Pain Medicine > Chapter 55 Painful Peripheral Neuropathies > Flashcards

Flashcards in Chapter 55 Painful Peripheral Neuropathies Deck (108):
1

Neuropathy

a general term used to describe disease of
nerve function and structures

2

Neuropathies arise from
many different etiologies

diabetic peripheral neuropathy, postherpetic neuropathy, chemotherapy-induced
peripheral neuropathy, HIV neuropathy, and neuropathy of chronic renal failure) and can be painful or painless. They can affect the central nervous system (CNS), the
peripheral nervous system, or both simultaneously.

3

Neuropathies result from

physical injury, inherited genetic disorders, infection, autoimmune disorders, and most often systemic disease.

4

mononeuropathy

polyneuropathy

Neuropathies can affect solely one single nerve, termed a mononeuropathy, or several separate
nerves, which is termed a polyneuropathy.

5

nociceptive pain

Pain is considered a normal, adaptive, or physiologic response when it results from nociceptors (pain receptors) having been activated by tissue disease or damage

6

neuropathic pain arises
from

spontaneous activity within the nervous system, or
an aberrant response to “normal” sensory stimulation (e.g., fine touch evoking pain).

7

Mononeuropathy multiplex

reflects changes
in multiple single, discreet nerves.

8

Polyneuropathy

reflects changes in sensation in a diffuse, often bilateral, pattern
that is not restricted to discreet nerves

9

Neuritis

a subtype
of neuropathy reserved for an inflammatory process
affecting the nerves.

10

Neuropathic pain

defined as pain initiated or
caused by a primary lesion or dysfunction in the nervous system has been revised to now include “pain arising as direct consequence of a lesion or disease affecting the
somatosensory system

11

Neuropathic pain can result from multiple causes and it can be categorized according to the site of initial injury

(central nervous system, peripheral nervous system, or mixed) and
the condition causing disease.

12

Paresthesias

Abnormal nonpainful sensations that may be spontaneous or evoked (tingling or “pins and needles” sensations

13

Dysesthesias

Abnormal pain that may be spontaneous or evoked
(unpleasant tingling)

14

Hyperpathia

An exaggerated painful response evoked by a noxious or
non-noxious stimulus

15

Allodynia

A painful response to a normally non-noxious stimulus
(e.g., light touch is perceived as burning pain)

16

Hyperalgesia

An exaggerated painful response to a normally noxious stimulus

17

Spontaneous pain

Painful sensation with no apparent external
stimulation

18

mechanisms are thought to be responsible for the
development of neuropathic pain

These include changes
in ion channel number and density resulting in central and peripheral sensitization. Other changes include cortical
reorganization and disinhibition of neuronal circuitry, and cellular and molecular changes as a result of the immune
response following the initial nerve damage. The sympathetic nervous system is also thought to play a role in maintaining neuropathic pain

19

Following trauma to a nerve, sodium channels

accumulate in a higher than normal concentration around the area of injury and along the entire axon, resulting in hypersensitivity
of the nerve and ectopic foci

20

nerve injury can result in the release of

neuropeptides that might further cause peripheral sensitization through neurogenic inflammation. Nerve injury also can result in sprouting of sympathetic fibers into the dorsal root ganglia of the affected nerve.

21

The CNS undergoes changes with peripheral nerve injury.

peripheral neuropathy results in reduced input to the CNS (postherpetic neuralgia, diabetic neuropathy).

22

In diabetic neuropathy, there is little evidence
that peripheral sensitization

as might be seen with
increased sodium channels or with ephaptic transmission) occurs; rather the evidence points toward reduced neural input to the CNS.

23

potential mechanisms exist for a central contribution to the pain from peripheral neuropathy

Loss of large fiber (A-b) sensory input could result in a reduction in non-nociceptive sensory input, thereby reducing the effectiveness of the “gate.” opioid and GABA receptors (both involved in inhibition of nociceptive transmission in the CNS) are down regulated and the amount of GABA in the dorsal horn is reduced. death of dorsal horn interneurons in lamina II (many of which
are involved in inhibition of nociceptive transmission in the dorsal horn) by overexposure to excitatory amino acids. Cholecystokinin, involved in opioid receptor inhibition, has also been found to be upregulated in the spinal cord following experimental nerve injury

24

Common Conditions Causing Neuropathic Pain Syndromes

Physical Injury/Trauma

Complex regional pain syndrome (CRPS), Type I & II Radiculopathy
Stroke (cerebrovascular accident)
Spinal cord injury

25

Common Conditions Causing Neuropathic Pain Syndromes

Inherited/Genetic

Charcot-Marie-Tooth
Fabry’s disease

26

Common Conditions Causing Neuropathic Pain Syndromes

Infections/Autoimmune

Human immunodeficiency virus
Herpes simplex virus
Acute inflammatory demyelinating polyneuropathy

27

Common Conditions Causing Neuropathic Pain Syndromes

Systemic Disease

Diabetes mellitus
Kidney disorders/renal failure
Vitamin deficiencies (beriberi, alcoholic pellagra,
vitamin B12 deficiency)
Vascular disorders
Chemical toxins (isoniazid, chemotherapy agents)
(platinum, vinca alkaloids, taxanes), arsenic, thallium
Hypothyroidism
Amyloidosis
Multiple myeloma

28

A central mechanism that may explain the allodynia seen
in some peripheral neuropathies involves

A-b fiber sprouting and A-b fiber “phenotypic switching.” A-b fibers
normally synapse in all lamina of the spinal cord except lamina II, where C-fiber input predominates. However, following peripheral C-fiber nerve injury, A-b fiber “sprouting” into lamina II occurs, therefore allowing mechanical non-nociceptive input via the peripheral A-b fibers to trigger second-order pain pathways.

29

A-b fibers in the dorsal horn do not normally express substance P (as seen in C-fibers), but following peripheral nerve injury

they can (phenotypic switching). When this happens, they thereby
allow non-nociceptive input to trigger CNS nociceptive transmission.

30

patient presents with signs and symptoms suggestive of neuropathic pain

allodynia, hypoand/
or hyper-algesia, and paresthesias

31

Focal lesions of peripheral nerves (mononeuropathies) result frequently from

processes that produce localized damage
and include nerve entrapment; mechanical injuries; thermal, electrical, or radiation injuries; vascular lesions; and neoplastic or infectious processes

32

polyneuropathies often result in

a bilateral and symmetric disturbance in function as a result of agents that act diffusely on the peripheral nervous system: toxic substances, deficiency states, metabolic disorders, and immune reactions

33

the most important pieces of historical information

The location of the pain and other symptoms

34

In the patient suspected of having polyneuropathy, the clinician should focus on

sensory evaluation. Strength and deep tendon reflexes are preserved in many patients with
polyneuropathy. In addition to testing vibration, proprioception,
and light touch, the sensory examination should include several special stimuli including light-touch rubbing, ice, single pinprick, and multiple pinpricks.

35

sensory evaluation

Lightly stroking the affected area with a finger will assess for allodynia (pain provoked by non-noxious stimuli). Ice
application will test for both temperature sensation and abnormal sensations such as pain and lingering after sensations. Single pinprick testing may elicit a sensory
deficit or hyperpathia. Repeated pinprick testing may elicit summation (pain growing more intense with subsequent stimuli) or lingering after sensations, both common findings in polyneuropathy

36

Patients suspected of having polyneuropathy can be considered
for what ELECTRODIAGNOSTIC TESTING

electromyography (EMG) and nerve conduction velocity (NCV) studies, which may offer insights into whether the process is a demyelinating (reductions in nerve conduction velocities) or axonal (reductions in the
amplitude of evoked responses) neuropathy.

37

Quantitative sensory testing (QST) may be the most useful in

the assessment and longitudinal monitoring of painful peripheral neuropathies. While large fibers are assessed through the use of sensory thresholds to vibration, small fibers can be assessed by
threshold for detection of heat, painful heat, cold, and painful cold stimuli.

38

cause of diabetic neuropathy

has not been determined
with certainty. Current hypotheses focus on the
possibilities of metabolic and ischemic nerve injury.
Pathologic examination of nerves taken from diabetic
patients has shown evidence of microvascular disease supporting
the ischemic nerve theory

39

Metabolic abnormalities of diabetic neuropathy
include

(1) accumulation of sorbitol in diabetic nerve as excess glucose is converted to sorbitol by the enzyme
aldose-reductase,
(2) autooxidation of glucose resulting in
reactive oxygen molecules, and
(3) inappropriate activation
of protein kinase C.

40

Diabetic neuropathy can be divided by the pattern of distribution of involved nerves

Mononeuropathy
- Cranial mononeuropathy
- Compression mononeuropathy

Mononeuropathy multiplex - Proximal motor neuropathy
- Truncal neuropathy

Polyneuropathy
- Distal symmetric polyneuropathy
- Painful diabetic neuropathy
- Autonomic polyneuropathy

41

distal symmetric
polyneuropathy

most common form of diabetic neuropathy. It is predominantly a sensory disturbance. Patients often present with gradual onset of paresthesias
and pain in the legs and feet. Symptoms begin in the toes and gradually ascend over months to years to involve more
proximal levels. The fingertips and hands become involved later, usually when symptoms in the lower extremities have ascended to the knee level. Allodynia and burning pain are common and are often worse
at night.

42

in Diabetic neuropathy
distal symmetric
polyneuropathy
Examination shows

graded distal sensory loss
predominantly affecting vibration and position sensation. Reflexes may be diminished or absent.

43

in Diabetic neuropathy
distal symmetric
Electrophysiologic testing shows

a decrease in the amplitude of evoked
responses to a greater degree than reduction in nerve conduction velocities as the neuropathy progresses. This reflects primarily axonal damage rather than demyelination

44

Severe sensory loss may allow repeated trauma to go unnoticed, resulting in

development of foot ulcers and diabetic
neuroarthropathy (Charcot’s joints)

45

syndrome of acute painful diabetic neuropathy

characterized by the rapid onset of severe pain in the distal lower extremities characterized by constant burning in the feet, dysesthesia, allodynia, and lancinating leg pains.

46

In syndrome of acute painful diabetic neuropathy Examination shows

little or no sensory loss with preserved reflexes. Electrophysiologic testing shows decreased amplitude or absent sensory potentials, but may also be normal. This type of neuropathy often remits within a year after blood sugars are controlled

47

Autonomic neuropathy

Symptomatic autonomic neuropathy most often occurs as a component of distal symmetric polyneuropathy. Autonomic nervous system abnormalities include postural hypotension, impaired heart rate control (resting
tachycardia and fixed heart rate), esophageal dysmotility, gastroparesis, and erectile dysfunction.

48

Lower extremity proximal motor neuropathy

an uncommon painful disorder associated with diabetes. It is characterized by acute or subacute onset of moderate to marked weakness and wasting of the pelvifemoral muscles
accompanied by back, hip, and thigh pain with preserved sensation in the regions of pain. The condition may be
painless or accompanied by pain described as a constant, severe, deep ache.

49

Diabetic lumbosacral radiculoplexus neuropathy (DLRPN)

referred to as diabetic amyotrophy, proximal
diabetic neuropathy, diabetic polyradiculopathy, Bruns- Garland syndrome, or diabetic lumbar plexopathy. It usually affects individuals with diabetes mellitus Type II
over the age of 50 years, and presents as an asymmetric weakness associated with pain in the legs that appears subacutely and progresses over weeks to months. Although motor function recovery is slow and often incomplete, the
pain usually resolves.

50

Diabetic truncal neuropathy involves

acute or gradual
onset of unilateral pain in the chest or abdomen and may mimic myocardial infarction, intra-abdominal pathology, or spinal disorders. Examination shows marked allodynia
and hyperpathia in the distribution of pain. EMG typically demonstrates denervation in the abdominal or intercostal musculature

51

Cranial mononeuropathies

involving the oculomotor,
abducens, trochlear, and facial nerves may occur in diabetic patients. The most common of these is oculomotor neuropathy that is manifest as ophthalmoplegia and ptosis. The eye is deviated laterally and has impaired movement
vertically and medially

52

Entrapment neuropathies are believed to occur more frequently in patients with diabetes mellitus

Carpal tunnel syndrome is believed to occur more than twice as frequently as in the nondiabetic population.

53

Amyloidosis

a disease caused by extracellular deposition of amyloid, a fibrous protein. Amyloidosis can be primary, familial, or
associated with other conditions such as multiple myeloma,
chronic infectious or inflammatory states, aging, and longterm hemodialysis.

54

characterize painful peripheral neuropathy in amyloidosis.

Deep aching and occasional shooting pains, distal sensory
loss, and autonomic and motor involvement

55

Treatment of
neuropathy associated with amyloidosis is aimed at

the underlying condition when such is identifiable

56

Multiple myeloma

due to malignant plasma cell growth. Painful neuropathy can appear in myeloma with or without
amyloid deposition. The neuropathy is extremely variable in severity and rate of progression, ranging from a mild, predominantly sensory neuropathy to a complete tetraplegia. Pain in myeloma often declines with successful treatment
using chemotherapy, radiation therapy (especially for isolated
plasmocytomas), or plasmapheresis.

57

untreated hypothyroidism may develop painful sensorimotor neuropathy

present with longstanding pain in either the hands
or the feet accompanied by weakness in the distal limb musculature.
The neuropathy often resolves with successful
replacement of thyroid hormone.

58

Thiamine deficiency seen in

alcoholics, chronic dialysis
patients, and people on restrictive diets

59

Thiamine deficiency
lead to beriberi

consists of heart failure, vasodilatation, and peripheral neuropathy. Hand foot, and calf pains with allodynia, decreased sensation, and motor involvement characterize the neuropathy.

60

Alcoholic neuropathy is characterized by

motor and sensory deficits, often accompanied by pain.
The pain consists of aching in the legs or feet with intermittent
lancinating pains. The upper limbs are rarely
involved. Burning of the soles and allodynia may also occur.

61

Alcoholic neuropathy occurs only after

chronic and severe alcohol abuse and is invariably accompanied
by severe nutritional deficiency. Treatment
consists of abstinence and thiamine supplementation.

62

Pellagra

caused by niacin deficiency and is rarely
seen in developed countries. Signs and symptoms include dermatitis, gastrointestinal complaints, neurasthenia, and spinal cord dysfunction. Pellagra is associated with a mixed, painful polyneuropathy similar to that seen with
beriberi.

63

In Pellagra a predominant feature of the sensorimotor neuropathy
is

spontaneous pain in the feet and lower legs,
with tenderness of the calf muscles and cutaneous hyperesthesia
of the feet

64

Treatment of pellagra

with niacin often results in resolution of all symptoms except the peripheral neuropathy.

65

Isoniazid

is a frequently used antituberculous drug.
Chronic administration in individuals with slow metabolism of the drug (slow acetylators) is associated with the
development of painful neuropathy.

66

Isoniazid neuropathy Initial symptoms

distal numbness and tingling paresthesias are later accompanied by pain, which may be felt as a deep ache or burning.
The calf muscles are painful and tender, and walking often aggravates symptoms. Symptoms may be particularly
troublesome at night.

67

Isoniazid neuropathy treatment

Prophylactic coadministration of
pyridoxine (vitamin B6) prevents development of neuropathy; however, it is not therapeutic once the neuropathy develops

68

most common neurologic complication of cancer treatment is

chemotherapy-induced peripheral neuropathy
(CIPN), a common adverse effect of treatment with
platinum-derived, taxane, and vinca alkaloid chemotherapeutic
compounds. These chemotherapeutic agents exert their cytotoxic effect by binding to DNA and producing interstrand and intrastrand cross-linkage,
thus impairing DNA synthesis and transcription.

69

The development
of CIPN is the most common reason a

platinum- based chemotherapy regimen is changed to another agent, administered at a lower dose, or given in fewer or
less frequent cycles of therapy.

70

chemotherapy-induced peripheral neuropathy
(CIPN) earliest manifestations of neuropathy

decreased vibration
sense in the toes and loss of ankle jerk reflexes. At larger doses, paresthesias may appear and progress to severe dysesthesias. The neuropathy is reversible, but recovery may take more than a year after discontinuation of the agent.

71

Charcot-Marie-Tooth (CMT) disorders are subdivided into

demyelinating and
axonal forms, depending on EMG conduction studies

72

Most common symptoms in Charcot-Marie-Tooth

include lower extremity
motor symptoms (foot deformity, difficulty ambulating), hyporeflexia, and sensory loss.

73

infectious neuropathies are very common

Mycobacterium leprae, although quite uncommon
in North America and Europe, is among the leading cause. It usually affects the skin and nerves, but there also exists a pure neural leprosy in about 4% to 10%40 of all leprosy
cases. Symptoms are found primarily in the form of mononeuritis
or mononeuritis multiplex.

74

The sensory neuropathies associated
with HIV (HIV-SN) include

distal sensory polyneuropathy
(DSP) due to the viral infection and antiretroviral toxic neuropathy (ATN) due to the medical treatment of
the viral illness.

75

The onset of DSP can occur in either

the subacute or chronic phases, or following the
development of an AIDS-defining illness

76

The clinical
manifestation of antiretroviral toxic neuropathy (ATN)

can appear within the first week to 6 months of the initiation of antiretroviral therapy and may subside after its cessation. The painful peripheral
neuropathy results from both direct neuronal inflammatory injury to the nerve itself (DSP) and the treatment using HAARTs leading to mitochondrial dysfunction

77

The clinical features of HIV-SN

are dominated by painful
dysesthesia, allodynia, and hyperalgesia. Onset is
often gradual and most commonly begins with bilateral lower extremity involvement. The neuropathy progresses
in a length-dependent fashion with a worsening
gradient of disease from distal structures to those more proximal.

78

HIV-SN symptoms

The dysesthesias commonly first involve
the soles of the feet and progress proximally; when the symptoms encompass the dermatomes of the knee the patient will often report finger involvement. The first symptoms noted are often numbness or burning sensation following a diurnal cycle with the pain worse
at night. Shortly thereafter, patients will report allodynia and hyperalgesia of the involved structures.

79

In HIV- SN, as a result, wearing shoes and walking become

painful and the patient’s
gait becomes antalgic.

80

In HIV- SN motor involvement

There is minimal subjective or objective motor involvement and it is generally limited to the intrinsic muscles of the foot. Physical examination
shows a diminution or loss of ankle reflexes in
addition to the sensory findings.

81

Reactivation of a latent infection of varicella zoster virus (human herpes virus-3) in the trigeminal ganglia or the dorsal root ganglia can result in

facial or peripheral pain in
the dermatomal distribution of the affected nerves. The resulting condition herpes zoster or “shingles” can be
excruciatingly painful and can result in a chronic pain condition called postherpetic neuralgia (PHN).

82

risk factors for the
development of PHN.

Advanced age, greater severity of the rash, and presence and severity of a painful prodrome preceding the rash

83

clinical presentation of PHN

common in the thoracolumbar region, following a single or multiple dermatomes with a prodromal period followed by the eruption of a maculopapular vesicular rash. The pain is most often described as burning, stabbing, and/or
throbbing and is commonly associated with cutaneous allodynia of the region.

84

Prevention of PHN
in patients who had a herpes zoster reactivation was successful in those

who received acyclovir

85

Acute inflammatory demyelinating polyradiculoneuropathy
(AIDP) caused by Guillain-Barré syndrome (GBS) is
characterized by

areflexic and ascending motor paralysis with sensory paresthesias. It is often preceded by an infection, generally an upper respiratory tract infection or gastroenteritis.
Most frequently, if an agent is identified, EBV,
CMV, Mycoplasma pneumoniae, and Campylobacter jejuni are found

86

Guillain-Barré syndrome (GBS) symptoms

The onset of symptoms develops over several days, or more frequently, weeks. Pain is a common early symptom; weakness, usually in the legs, may progress to respiratory failure requiring mechanical ventilation. Sensory symptoms include paresthesias often
in the presence of decreased sensation in a glove-stocking
distribution. Autonomic dysfunction is also commonly evidenced by tachycardia and orthostatic hypotension.

87

Guillain-Barré syndrome (GBS) pain

The pain is principally
an ache, strain, or deep burning sensation in the
thigh or buttocks and can be quite severe. While pain in AIDP may be severe, it is usually transient. Pain is usually worse at night.

88

Guillain-Barré syndrome (GBS) diagnosis and treatment

Nerve conduction studies and lumbar puncture aid the diagnosis. General therapy for AIDP (Acute inflammatory demyelinating polyradiculoneuropathy) is supportive along with plasmapheresis and IVIG. Glucocorticoids and other immunosuppressants have not been clearly shown to be helpful.

89

IDIOPATHIC SMALL-FIBER NEUROPATHY

This condition usually presents with painful feet in patients over age 60. It can be defined as the presence of paresthesias (usually painful) with the
absence of significant large-fiber dysfunction (atrophy, loss of vibratory sense, or loss of reflexes). Diagnosis is often confirmed through tests of autonomic function, quantitative sensory testing, or skin biopsy

90

antidepressants treatment of peripheral neuropathic pain

TCAs (amitriptyline, nortriptyline, desipramine,
imipramine) are the best studied and most efficacious, followed
by SNRIs (duloxetine, venlafaxine) and then SSRIs (citalopram, paroxetine).

91

The side effect profile of the TCAs, primarily anticholinergic effects, limits their widespread
application, especially in patients with

autonomic neuropathy, glaucoma, cardiac arrhythmias, and urinary
hesitation.

92

Anticonvulsants are used very frequently and successfully

gabapentin and pregabalin, structural
analogs to (GABA), are considered first-line agents and are used in the treatment of a
multitude of neuropathic pain syndromes including radiculopathy,
CRPS Type I and II, diabetic neuropathy, postherpetic
neuralgia, and mixed neuropathic pain conditions.

93

Anticonvulsants side effects

sedation, dizziness, GI complaints, and lower extremity edema

94

Other antiepileptics shown to bring symptomatic relief
such as in

HIV neuropathy (lamotrigine), painful diabetic neuropathy (lacosamide), and postherpetic neuralgia (valproic acid)

95

Other oral medications that have shown beneficial effects but are generally employed in refractory cases or as second-line agents, include

opioids such as morphine or tramadol

96

treatment options that
have shown improvement in neuropathic pain include topical agents such as

lidocaine patches (postherpetic neuralgia,
post-traumatic neuralgia) or in experimental studies,
high-concentration (8%) capsaicin creams (HIV neuropathy, postherpetic neuralgia

97

treatment of patient without significant relief of their neuropathic
pain.

In these circumstances, various alternative options
exist, including sympathetic nerve blocks, neurolytic sympathetic blocks, spinal cord stimulation (SCS), deep
brain stimulation (DBS), transcutaneous electrical nerve stimulation (TENS), and repetitive transcranial magnetic stimulation (rTMS).

98

The use of spinal cord stimulation is well established in

neuropathic pain
conditions including postlaminectomy syndrome, CRPS
Type I, and diabetic peripheral neuropathy

99

Gabapentin

Start Dose:100–300 mg/day
Maximum Dose: 3600 mg/day
Documented Effect: PHN, PDN, HIV, mixed
neuropathic pain
Side Effects: Sedation, dizziness, edema

100

Pregabalin

Start Dose: 50–150 mg/day
Maximum Dose: 300 mg/day, (600 mg/day
fibromyalgia)
Documented Effect: PHN, PDN, mixed neuropathic
pain, fibromyalgia, central pain
Side Effects: Sedation, dizziness, edema

101

Tricyclic
antidepressants (Nortriptyline, Desipramine
Trazadone)

Start Dose: 10–25 mg/day
Maximum Dose: 50–150 mg/day
Documented Effect: PHN, PDN, central pain,
mixed neuropathic pain
Side Effects: Cardiac, anticholinergic,
sedation

102

Specific serotonergic
and noradrenergic
reuptake inhibitors (Venlafaxine, Duloxetine)

Start Dose: 37.5 mg/day
20 mg/day
Maximum Dose: 25–375 mg/day, 60 mg/day
Documented Effect: PHN, PDN, fibromyalgia
Side Effects: Sedation

103

Carbamazepine

Start Dose: 300 mg/day
Maximum Dose: 1200–1800 mg (1/3 higher
dose for oxcarbazepine)
Documented Effect: Trigeminal neuralgia
Side Effects: Sedation, dizziness, ataxia,
blood dyscrasias

104

Tramadol

Start Dose: 50–150 mg/day
Maximum Dose: 400 mg/day
Documented Effect: PHN, PDN
Side Effects: Sedation, dizziness, seizure

105

Lamotrigine

Start Dose: 25 mg/day
Maximum Dose: 400–600 mg/day
Documented Effect: Trigeminal neuralgia,
poststroke central pain, HIV
Side Effects: Sedation, tremor, rash

106

Opioids

Start Dose: 5–10 mg/day; titrate and substitute with
long-acting opioids
Maximum Dose: Variable, 100–200 mg (OME)/day
Documented Effect: PHN, PDN, post–amputation
pain
Side Effects: Sedation, dizziness, tolerance, drug abuse, misuse

107

Lidocaine patch

Start Dose: 5%
Maximum Dose: 3 patches/day
Documented Effect: PHN, traumatic nerve injury
Side Effects: Allergic reaction

108

Capsaicin cream

Start Dose: 0.025% and 0.075%
Maximum Dose: N/A
Documented Effect: PHN, PDN, HIV

Decks in Essentials of Pain Medicine Class (80):